Request Free Sample ×
Chronic Idiopathic Constipation Market Research Report – Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Chronic Idiopathic Constipation Market

ID: MRFR/Pharma/4475-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Chronic Idiopathic Constipation Market Research Report Information By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), Treatment (Drugs), End-User (Hospitals & Clinics, Diagnostic Centers) -Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Chronic Idiopathic Constipation Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Diagnosis (USD Billion)
  49.     4.1.1 blood tests
  50.     4.1.2 sigmoidoscopy
  51.     4.1.3 colonoscopy
  52.     4.1.4 balloon expulsion test
  53.     4.1.5 anorectal manometry
  54.     4.1.6 colonic transit study
  55.     4.1.7 defecography
  56.     4.1.8 others
  57.   4.2 Healthcare, BY Treatment (USD Billion)
  58.     4.2.1 drugs
  59.     4.2.2 surgery
  60.     4.2.3 acid neutralizers
  61.     4.2.4 laxatives and antidiarrheal
  62.     4.2.5 antiemetics
  63.     4.2.6 antiulcer
  64.     4.2.7 lubiprostone (amitiza)
  65.     4.2.8 linaclotide (linzess)
  66.     4.2.9 misoprostol (Cytotec)
  67.     4.2.10 colchicine/probenecid (Col-Probenecid)
  68.     4.2.11 others
  69.     4.2.12 Onabotulinumtoxin A (Botox)
  70.   4.3 Healthcare, BY End-User Industries (USD Billion)
  71.     4.3.1 hospitals
  72.     4.3.2 gastroenterology clinics
  73.     4.3.3 diagnostic centers
  74.     4.3.4 others
  75.   4.4 Healthcare, BY Region (USD Billion)
  76.     4.4.1 North America
  77.       4.4.1.1 US
  78.       4.4.1.2 Canada
  79.     4.4.2 Europe
  80.       4.4.2.1 Germany
  81.       4.4.2.2 UK
  82.       4.4.2.3 France
  83.       4.4.2.4 Russia
  84.       4.4.2.5 Italy
  85.       4.4.2.6 Spain
  86.       4.4.2.7 Rest of Europe
  87.     4.4.3 APAC
  88.       4.4.3.1 China
  89.       4.4.3.2 India
  90.       4.4.3.3 Japan
  91.       4.4.3.4 South Korea
  92.       4.4.3.5 Malaysia
  93.       4.4.3.6 Thailand
  94.       4.4.3.7 Indonesia
  95.       4.4.3.8 Rest of APAC
  96.     4.4.4 South America
  97.       4.4.4.1 Brazil
  98.       4.4.4.2 Mexico
  99.       4.4.4.3 Argentina
  100.       4.4.4.4 Rest of South America
  101.     4.4.5 MEA
  102.       4.4.5.1 GCC Countries
  103.       4.4.5.2 South Africa
  104.       4.4.5.3 Rest of MEA
  105. 5 SECTION V: COMPETITIVE ANALYSIS
  106.   5.1 Competitive Landscape
  107.     5.1.1 Overview
  108.     5.1.2 Competitive Analysis
  109.     5.1.3 Market share Analysis
  110.     5.1.4 Major Growth Strategy in the Healthcare
  111.     5.1.5 Competitive Benchmarking
  112.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  113.     5.1.7 Key developments and growth strategies
  114.       5.1.7.1 New Product Launch/Service Deployment
  115.       5.1.7.2 Merger & Acquisitions
  116.       5.1.7.3 Joint Ventures
  117.     5.1.8 Major Players Financial Matrix
  118.       5.1.8.1 Sales and Operating Income
  119.       5.1.8.2 Major Players R&D Expenditure. 2023
  120.   5.2 Company Profiles
  121.     5.2.1 AbbVie (US)
  122.       5.2.1.1 Financial Overview
  123.       5.2.1.2 Products Offered
  124.       5.2.1.3 Key Developments
  125.       5.2.1.4 SWOT Analysis
  126.       5.2.1.5 Key Strategies
  127.     5.2.2 Boehringer Ingelheim (DE)
  128.       5.2.2.1 Financial Overview
  129.       5.2.2.2 Products Offered
  130.       5.2.2.3 Key Developments
  131.       5.2.2.4 SWOT Analysis
  132.       5.2.2.5 Key Strategies
  133.     5.2.3 Takeda Pharmaceutical Company (JP)
  134.       5.2.3.1 Financial Overview
  135.       5.2.3.2 Products Offered
  136.       5.2.3.3 Key Developments
  137.       5.2.3.4 SWOT Analysis
  138.       5.2.3.5 Key Strategies
  139.     5.2.4 Ironwood Pharmaceuticals (US)
  140.       5.2.4.1 Financial Overview
  141.       5.2.4.2 Products Offered
  142.       5.2.4.3 Key Developments
  143.       5.2.4.4 SWOT Analysis
  144.       5.2.4.5 Key Strategies
  145.     5.2.5 Sucampo Pharmaceuticals (US)
  146.       5.2.5.1 Financial Overview
  147.       5.2.5.2 Products Offered
  148.       5.2.5.3 Key Developments
  149.       5.2.5.4 SWOT Analysis
  150.       5.2.5.5 Key Strategies
  151.     5.2.6 AstraZeneca (GB)
  152.       5.2.6.1 Financial Overview
  153.       5.2.6.2 Products Offered
  154.       5.2.6.3 Key Developments
  155.       5.2.6.4 SWOT Analysis
  156.       5.2.6.5 Key Strategies
  157.     5.2.7 Salix Pharmaceuticals (US)
  158.       5.2.7.1 Financial Overview
  159.       5.2.7.2 Products Offered
  160.       5.2.7.3 Key Developments
  161.       5.2.7.4 SWOT Analysis
  162.       5.2.7.5 Key Strategies
  163.     5.2.8 GSK (GB)
  164.       5.2.8.1 Financial Overview
  165.       5.2.8.2 Products Offered
  166.       5.2.8.3 Key Developments
  167.       5.2.8.4 SWOT Analysis
  168.       5.2.8.5 Key Strategies
  169.     5.2.9 MediGene AG (DE)
  170.       5.2.9.1 Financial Overview
  171.       5.2.9.2 Products Offered
  172.       5.2.9.3 Key Developments
  173.       5.2.9.4 SWOT Analysis
  174.       5.2.9.5 Key Strategies
  175.   5.3 Appendix
  176.     5.3.1 References
  177.     5.3.2 Related Reports
  178. 6 LIST OF FIGURES
  179.   6.1 MARKET SYNOPSIS
  180.   6.2 NORTH AMERICA MARKET ANALYSIS
  181.   6.3 US MARKET ANALYSIS BY DIAGNOSIS
  182.   6.4 US MARKET ANALYSIS BY TREATMENT
  183.   6.5 US MARKET ANALYSIS BY END-USER INDUSTRIES
  184.   6.6 CANADA MARKET ANALYSIS BY DIAGNOSIS
  185.   6.7 CANADA MARKET ANALYSIS BY TREATMENT
  186.   6.8 CANADA MARKET ANALYSIS BY END-USER INDUSTRIES
  187.   6.9 EUROPE MARKET ANALYSIS
  188.   6.10 GERMANY MARKET ANALYSIS BY DIAGNOSIS
  189.   6.11 GERMANY MARKET ANALYSIS BY TREATMENT
  190.   6.12 GERMANY MARKET ANALYSIS BY END-USER INDUSTRIES
  191.   6.13 UK MARKET ANALYSIS BY DIAGNOSIS
  192.   6.14 UK MARKET ANALYSIS BY TREATMENT
  193.   6.15 UK MARKET ANALYSIS BY END-USER INDUSTRIES
  194.   6.16 FRANCE MARKET ANALYSIS BY DIAGNOSIS
  195.   6.17 FRANCE MARKET ANALYSIS BY TREATMENT
  196.   6.18 FRANCE MARKET ANALYSIS BY END-USER INDUSTRIES
  197.   6.19 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
  198.   6.20 RUSSIA MARKET ANALYSIS BY TREATMENT
  199.   6.21 RUSSIA MARKET ANALYSIS BY END-USER INDUSTRIES
  200.   6.22 ITALY MARKET ANALYSIS BY DIAGNOSIS
  201.   6.23 ITALY MARKET ANALYSIS BY TREATMENT
  202.   6.24 ITALY MARKET ANALYSIS BY END-USER INDUSTRIES
  203.   6.25 SPAIN MARKET ANALYSIS BY DIAGNOSIS
  204.   6.26 SPAIN MARKET ANALYSIS BY TREATMENT
  205.   6.27 SPAIN MARKET ANALYSIS BY END-USER INDUSTRIES
  206.   6.28 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
  207.   6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
  208.   6.30 REST OF EUROPE MARKET ANALYSIS BY END-USER INDUSTRIES
  209.   6.31 APAC MARKET ANALYSIS
  210.   6.32 CHINA MARKET ANALYSIS BY DIAGNOSIS
  211.   6.33 CHINA MARKET ANALYSIS BY TREATMENT
  212.   6.34 CHINA MARKET ANALYSIS BY END-USER INDUSTRIES
  213.   6.35 INDIA MARKET ANALYSIS BY DIAGNOSIS
  214.   6.36 INDIA MARKET ANALYSIS BY TREATMENT
  215.   6.37 INDIA MARKET ANALYSIS BY END-USER INDUSTRIES
  216.   6.38 JAPAN MARKET ANALYSIS BY DIAGNOSIS
  217.   6.39 JAPAN MARKET ANALYSIS BY TREATMENT
  218.   6.40 JAPAN MARKET ANALYSIS BY END-USER INDUSTRIES
  219.   6.41 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
  220.   6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
  221.   6.43 SOUTH KOREA MARKET ANALYSIS BY END-USER INDUSTRIES
  222.   6.44 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
  223.   6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT
  224.   6.46 MALAYSIA MARKET ANALYSIS BY END-USER INDUSTRIES
  225.   6.47 THAILAND MARKET ANALYSIS BY DIAGNOSIS
  226.   6.48 THAILAND MARKET ANALYSIS BY TREATMENT
  227.   6.49 THAILAND MARKET ANALYSIS BY END-USER INDUSTRIES
  228.   6.50 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
  229.   6.51 INDONESIA MARKET ANALYSIS BY TREATMENT
  230.   6.52 INDONESIA MARKET ANALYSIS BY END-USER INDUSTRIES
  231.   6.53 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
  232.   6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT
  233.   6.55 REST OF APAC MARKET ANALYSIS BY END-USER INDUSTRIES
  234.   6.56 SOUTH AMERICA MARKET ANALYSIS
  235.   6.57 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
  236.   6.58 BRAZIL MARKET ANALYSIS BY TREATMENT
  237.   6.59 BRAZIL MARKET ANALYSIS BY END-USER INDUSTRIES
  238.   6.60 MEXICO MARKET ANALYSIS BY DIAGNOSIS
  239.   6.61 MEXICO MARKET ANALYSIS BY TREATMENT
  240.   6.62 MEXICO MARKET ANALYSIS BY END-USER INDUSTRIES
  241.   6.63 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
  242.   6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT
  243.   6.65 ARGENTINA MARKET ANALYSIS BY END-USER INDUSTRIES
  244.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
  245.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
  246.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER INDUSTRIES
  247.   6.69 MEA MARKET ANALYSIS
  248.   6.70 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
  249.   6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
  250.   6.72 GCC COUNTRIES MARKET ANALYSIS BY END-USER INDUSTRIES
  251.   6.73 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
  252.   6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
  253.   6.75 SOUTH AFRICA MARKET ANALYSIS BY END-USER INDUSTRIES
  254.   6.76 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
  255.   6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT
  256.   6.78 REST OF MEA MARKET ANALYSIS BY END-USER INDUSTRIES
  257.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  258.   6.80 RESEARCH PROCESS OF MRFR
  259.   6.81 DRO ANALYSIS OF HEALTHCARE
  260.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  261.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  262.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  263.   6.85 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
  264.   6.86 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
  265.   6.87 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
  266.   6.88 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
  267.   6.89 HEALTHCARE, BY END-USER INDUSTRIES, 2024 (% SHARE)
  268.   6.90 HEALTHCARE, BY END-USER INDUSTRIES, 2024 TO 2035 (USD Billion)
  269.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  270. 7 LIST OF TABLES
  271.   7.1 LIST OF ASSUMPTIONS
  272.     7.1.1
  273.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  274.     7.2.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  275.     7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
  276.     7.2.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  277.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  278.     7.3.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  279.     7.3.2 BY TREATMENT, 2025-2035 (USD Billion)
  280.     7.3.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  281.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  282.     7.4.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  283.     7.4.2 BY TREATMENT, 2025-2035 (USD Billion)
  284.     7.4.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  285.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  286.     7.5.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  287.     7.5.2 BY TREATMENT, 2025-2035 (USD Billion)
  288.     7.5.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  289.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  290.     7.6.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  291.     7.6.2 BY TREATMENT, 2025-2035 (USD Billion)
  292.     7.6.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  293.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  294.     7.7.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  295.     7.7.2 BY TREATMENT, 2025-2035 (USD Billion)
  296.     7.7.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  297.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  298.     7.8.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  299.     7.8.2 BY TREATMENT, 2025-2035 (USD Billion)
  300.     7.8.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  301.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  302.     7.9.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  303.     7.9.2 BY TREATMENT, 2025-2035 (USD Billion)
  304.     7.9.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  305.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  306.     7.10.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  307.     7.10.2 BY TREATMENT, 2025-2035 (USD Billion)
  308.     7.10.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  309.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  310.     7.11.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  311.     7.11.2 BY TREATMENT, 2025-2035 (USD Billion)
  312.     7.11.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  313.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  314.     7.12.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  315.     7.12.2 BY TREATMENT, 2025-2035 (USD Billion)
  316.     7.12.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  317.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  318.     7.13.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  319.     7.13.2 BY TREATMENT, 2025-2035 (USD Billion)
  320.     7.13.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  321.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  322.     7.14.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  323.     7.14.2 BY TREATMENT, 2025-2035 (USD Billion)
  324.     7.14.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  325.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  326.     7.15.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  327.     7.15.2 BY TREATMENT, 2025-2035 (USD Billion)
  328.     7.15.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  329.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  330.     7.16.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  331.     7.16.2 BY TREATMENT, 2025-2035 (USD Billion)
  332.     7.16.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  333.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  334.     7.17.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  335.     7.17.2 BY TREATMENT, 2025-2035 (USD Billion)
  336.     7.17.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  337.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  338.     7.18.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  339.     7.18.2 BY TREATMENT, 2025-2035 (USD Billion)
  340.     7.18.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  341.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  342.     7.19.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  343.     7.19.2 BY TREATMENT, 2025-2035 (USD Billion)
  344.     7.19.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  345.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  346.     7.20.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  347.     7.20.2 BY TREATMENT, 2025-2035 (USD Billion)
  348.     7.20.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  349.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  350.     7.21.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  351.     7.21.2 BY TREATMENT, 2025-2035 (USD Billion)
  352.     7.21.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  353.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  354.     7.22.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  355.     7.22.2 BY TREATMENT, 2025-2035 (USD Billion)
  356.     7.22.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  357.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  358.     7.23.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  359.     7.23.2 BY TREATMENT, 2025-2035 (USD Billion)
  360.     7.23.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  361.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  362.     7.24.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  363.     7.24.2 BY TREATMENT, 2025-2035 (USD Billion)
  364.     7.24.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  365.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  366.     7.25.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  367.     7.25.2 BY TREATMENT, 2025-2035 (USD Billion)
  368.     7.25.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  369.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  370.     7.26.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  371.     7.26.2 BY TREATMENT, 2025-2035 (USD Billion)
  372.     7.26.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  373.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  374.     7.27.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  375.     7.27.2 BY TREATMENT, 2025-2035 (USD Billion)
  376.     7.27.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  377.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  378.     7.28.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  379.     7.28.2 BY TREATMENT, 2025-2035 (USD Billion)
  380.     7.28.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  381.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  382.     7.29.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  383.     7.29.2 BY TREATMENT, 2025-2035 (USD Billion)
  384.     7.29.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  385.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  386.     7.30.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  387.     7.30.2 BY TREATMENT, 2025-2035 (USD Billion)
  388.     7.30.3 BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
  389.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  390.     7.31.1
  391.   7.32 ACQUISITION/PARTNERSHIP
  392.     7.32.1

Healthcare Market Segmentation

Healthcare By Diagnosis (USD Billion, 2025-2035)

  • blood tests
  • sigmoidoscopy
  • colonoscopy
  • balloon expulsion test
  • anorectal manometry
  • colonic transit study
  • defecography
  • others

Healthcare By Treatment (USD Billion, 2025-2035)

  • drugs
  • surgery
  • acid neutralizers
  • laxatives and antidiarrheal
  • antiemetics
  • antiulcer
  • lubiprostone (amitiza)
  • linaclotide (linzess)
  • misoprostol (Cytotec)
  • colchicine/probenecid (Col-Probenecid)
  • others
  • Onabotulinumtoxin A (Botox)

Healthcare By End-User Industries (USD Billion, 2025-2035)

  • hospitals
  • gastroenterology clinics
  • diagnostic centers
  • others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓